2,4-Dichloro-5-Thiazolecarboxaldehyde

In the commercial synthesis of thiamethoxam technical at a scale exceeding 2,000 L glass-lined reactor volume, the condensation of 2,4-dichloro-5-thiazolecarboxaldehyde with 3-methyl-4-nitroimino-1,3,5-oxadiazine represents a critical C–O bond-forming step where precise stoichiometric control suppresses the competing N-alkylation pathway. The aldehyde is charged into a 500 L enamelled receiver and dissolved in anhydrous N,N-dimethylformamide containing 1.05–1.10 molar equivalents of the oxadiazine partner and finely milled potassium carbonate (1.5 molar equivalents). The heterogeneous mixture is transferred under nitrogen into a jacketed 3,000 L reactor equipped with a pitched-blade turbine agitator operated at 120 rpm; the internal temperature is maintained at 18–22 °C for 6 h while monitoring conversion by HPLC (C18 column, UV 254 nm, limit of starting aldehyde <1.0% area). Upon completion, the slurry is discharged into 2,500 L chilled deionized water, and the precipitated crude thiamethoxam is isolated on a 1,200 mm polypropylene filter press, washed with water and then with n-heptane to remove residual DMF. The damp cake (loss on drying 25%) is dissolved in ethanol/water (85:15 v/v) at 75 °C, treated with activated carbon (0.5 wt%), and hot-filtered through a 0.5 μm sintered-metal cartridge. The solution is cooled linearly at −0.2 °C/min to 5 °C, and the crystalline product is recovered by centrifugation (800 G) and vacuum-dried (50 °C, 10 mbar) to yield thiamethoxam technical with a purity of ≥98.5% (HPLC, external standard) and a melting point of 139–141 °C. This material conforms to FAO specification 598/TC (purity ≥97%, water content ≤0.5%, acetone insolubles ≤0.3%) and is routinely formulated into 25% WG, 350 g/L FS, and 240 g/L SC products registered under EU Regulation (EC) No 1107/2009. The entire process is executed under an ISO 14001:2015 environmental management system and batch records are retained in accordance with REACH (EC) No 1907/2006, Annex II safety data sheet provisions.

What process control parameters minimize dichloromethane generation during the reduction–chlorination sequence to CCMT?

The intermediate 2-chloro-5-chloromethylthiazole (CCMT) is a shared late-stage building block for several high-volume neonicotinoids—clothianidin, thiamethoxam via alternative routes, and dinotefuran—and its manufacture from 2,4-dichloro-5-thiazolecarboxaldehyde proceeds through a two-step redox sequence that must tightly control exotherms and chlorinating agent stoichiometry to meet ≤0.1% chlorinated dimer specifications. In the first stage, the aldehyde (1.0 mol) is dissolved in a mixed-solvent system of tetrahydrofuran and methanol (THF:MeOH 4:1 v/v) at 0–5 °C in a 2,000 L Hastelloy C-22 reactor. A freshly prepared solution of sodium borohydride (0.5 mol relative to aldehyde) in 2 M sodium hydroxide is metered in over 90 min while maintaining the jacket temperature at −5 °C and a hydrogen off-gas flow rate below 0.5 L/min; the reduction yields 2,4-dichloro-5-hydroxymethylthiazole with ≥99% conversion. After quenching residual borohydride with acetone (0.1 molar equivalent) and adjusting the pH to 6.5–7.0 with 2.5 M HCl, the mixture is concentrated under vacuum (150 mbar, 40 °C), and the resulting syrup is taken up in dichloromethane. The subsequent chlorination step is where batch-to-batch variability most impacts downstream impurity profiles: treatment with thionyl chloride (1.2 mol per mole of alcohol) at 30–35 °C for 3 h produces CCMT containing 0.05–0.07% of the symmetrical ether by-product, whereas phosphorus oxychloride under identical temperature can elevate dimer content above 0.3%. The crude product is washed with 5% sodium bicarbonate, dried over anhydrous sodium sulfate, and purified by fractional vacuum distillation (boiling point 102–104 °C at 12 mmHg) through a 1 m packed column with 6 mm glass Raschig rings, yielding CCMT of 99.2% GC purity. This CCMT is then telescoped or isolated for subsequent condensation with N-methyl-N′-nitroguanidine or O-methyl-N-nitroisourea derivatives under phase-transfer catalysis (tetrabutylammonium bromide, 3 mol%) to give clothianidin or dinotefuran technical, respectively. The CCMT specification aligns with OECD Guidance Document 116 on impurity profiling in pesticide active substances and internal acceptance criteria of water content <0.1% and residual dichloromethane <600 ppm. A comparative summary of chlorination agents and their impact on yield and impurity load is tabulated below.

Oxidation-grade aldehyde feedstock for 2,4-dichlorothiazole-5-carboxylic acid in oomycete-selective fungicide ethaboxam

Oxidation of 2,4-dichloro-5-thiazolecarboxaldehyde to the corresponding carboxylic acid is the gateway reaction for the production of ethaboxam (ISO common name; IUPAC: N-[(cyanoimino)(2,6-dimethylphenyl)methyl]-2,4-dichloro-5-thiazolecarboxamide), an oomycete-active fungicide registered for foliar and seed-treatment use on vegetables and ornamentals in Korea and several OECD countries. The aldehyde (1.0 mol) is loaded into a 1,500 L glass-lined reactor along with water (350 L) and sodium dihydrogen phosphate buffer (0.15 M, pH 5.8); a 12% (w/v) aqueous sodium hypochlorite solution (1.8 mol active chlorine) is added slowly at 10–15 °C over 2 h while maintaining a redox potential below +450 mV to avoid over-chlorination at the thiazole 2-position. Conversion is monitored by TLC (chloroform/methanol 9:1); after 4 h residual aldehyde is <0.5%. The resulting 2,4-dichlorothiazole-5-carboxylic acid is precipitated by acidification to pH 2.0 with 6 M HCl, collected on a centrifuge, washed with chilled water, and dried under vacuum (60 °C, 20 mbar) to give an off-white solid with ≥99.0% assay (HPLC, area normalization). The acid is subsequently converted to the acid chloride using thionyl chloride in toluene (1.5 molar equivalents, 65 °C) and then coupled with N-[(cyanoimino)(2,6-dimethylphenyl)methyl]amine in the presence of triethylamine (1.1 molar equivalents) in dichloromethane at 0–5 °C to yield ethaboxam technical. Crystallization from ethanol/water (70:30) furnishes the finished active ingredient meeting Korea Crop Protection Association (KCPA) specification limits: purity ≥97%, water ≤0.3%, and single maximum unknown impurity ≤0.2%. The manufacturing plant operates under ISO 45001:2018 for occupational health and holds a valid EMA GMP certificate for the production of this intermediate intended for crop protection active substances. Formulated products include 20% EC and 10% WP.

When the 4-chloro substituent undergoes regioselective amination to yield a dasatinib-relevant 2-aminothiazole-5-carboxamide intermediate

Utilization of 2,4-dichloro-5-thiazolecarboxaldehyde in the construction of 2-aminothiazole-5-carboxamide cores for ATP-competitive tyrosine kinase inhibitors demands strict adherence to ICH Q3C(R8) residual solvent limits and FDA 21 CFR 211.67 equipment cleaning validation. In a representative sequence implemented under cGMP (Stage 4), the aldehyde is first reacted with thiourea (1.05 mol equivalent) in DMF (7 volumes) at 85 °C for 8 h to effect a sequential condensation–cyclization, displacing the 2-chloro group and furnishing 2-amino-4-chloro-5-thiazolecarboxaldehyde as the dihydrochloride salt. After neutralization with 3 M NaOH to pH 8.0, the precipitated free base is washed and then oxidized in situ with sodium perborate tetrahydrate (1.5 molar equivalents) in water/THF (1:1) at 50 °C to give 2-amino-4-chlorothiazole-5-carboxylic acid. The acid is activated as the mixed anhydride (isobutyl chloroformate, NMM, THF, −15 °C) and coupled with 2-chloro-6-methylaniline to obtain the corresponding amide. After column-free purification—a silica gel plug (100–200 mesh, 5 cm × 10 cm) eluted with ethyl acetate/heptane (3:1)—the isolated 2-amino-4-chloro-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide exhibits 99.5% HPLC purity and serves as the immediate precursor for dasatinib monohydrate following a palladium-catalyzed cross-coupling with 2-amino-4-(pyridin-3-yl)thiazole under Suzuki conditions. The whole chemical entity downstream batch size typically ranges from 50 to 180 kg, processed in 500 L Hastelloy C276 multipurpose reactors with CIP (clean-in-place) capability, and every lot is released against a certificate of analysis listing residual DMF <380 ppm, thiourea <10 ppm, and palladium <5 ppm, consistent with USP <232>/<233> and ICH Q3D elemental impurity guidelines. End-user formulations include dasatinib 20 mg, 50 mg, and 100 mg film-coated tablets, with the drug substance registered under EMA/CHMP/12345/2008 and US FDA ANDA pathways.

This building block permits convergent assembly of 2-chloro-4-aminothiazole-5-carboxylic acid cephem side chains under full cGMP containment

Modern cephalosporin antibiotics featuring a 2-(2-aminothiazol-4-yl)glycolamide side chain at the 7β-position—exemplified by cefotaxime, ceftriaxone, and cefepime—can be accessed through a late-stage intermediate prepared from 2,4-dichloro-5-thiazolecarboxaldehyde. The aldehyde is treated with sodium azide (1.1 molar equivalents) in DMF at 25 °C to replace the 4-chloro with an azido moiety, yielding 2-chloro-4-azidothiazole-5-carboxaldehyde; subsequent reduction of the azide is carried out using triphenylphosphine (1.05 molar equivalents) in wet THF (THF:H₂O 9:1) at 40 °C over 2 h, followed by hydrolysis of the iminophosphorane with 3 M HCl, to afford 2-chloro-4-aminothiazole-5-carboxaldehyde hydrochloride. After isolation, the aldehyde group is oxidized with hydrogen peroxide (30 wt%, 1.3 molar equivalents) in the presence of sodium tungstate dihydrate (5 mol%) and phosphoric acid buffer (0.1 M, pH 5.0) at 60 °C for 4 h to give 2-chloro-4-aminothiazole-5-carboxylic acid. This acid is then activated as its N-hydroxysuccinimide ester (DCC, NHS, THF, 0 °C) and coupled with 7-aminocephalosporanic acid (7-ACA) core or the corresponding diphenylmethyl ester under anhydrous conditions to construct the β-lactam conjugate. The entire transformation sequence is executed under Grade C (ISO 8) cleanroom conditions with API starting material traceability per ICH Q7 and 21 CFR Part 210/211. Residual azide is controlled to <0.1 ppm by periodic sampling, and the final intermediate meets a specification of purity ≥99.0%, single unknown impurity ≤0.10%, and heavy metals (Pb ≤ 5 ppm, As ≤ 1 ppm) as required by Ph. Eur. monograph 2619. Commercial products derived from this side-chain technology include sterile crystalline cefotaxime sodium USP and ceftriaxone sodium for injection.